Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV.PHPeB is an engineered adeno-associated virus (AAV) capsid platform derived from AAV9, specifically optimized for high-efficiency crossing of the blood-brain barrier (BBB) and widespread neuronal transduction following systemic (intravenous) administration. Developed at the California Institute of Technology, it is widely used in preclinical research to deliver gene modulation tools to the central nervous system. In the development of therapies for SCN2A haploinsufficiency, such as those by Regel Therapeutics, AAV.PHPeB has been utilized to screen and characterize neuron-specific regulatory elements (REs) and to deliver payloads like dCas9-VP64. These payloads are designed to upregulate the SCN2A gene, thereby restoring functional levels of the Nav1.2 sodium channel protein to treat associated neurodevelopmental disorders, including autism and epilepsy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AAV.PHPeB.